Dyne Therapeutics Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect three Class III directors (David Lubner, Brian Posner, and Jason Rhodes) to three-year terms expiring in 2029.

2. 2

   Advisory Vote on the Compensation of Our Named Executive Officers (Say-on-Pay

   ManagementBoard: FOR

   Non-binding advisory vote to approve the compensation of the company’s named executive officers as disclosed in the proxy statement.

   More detail

   The proposal asks shareholders to approve, on a non-binding advisory basis, the compensation disclosed for named executive officers (NEOs). Management seeks approval to validate executive pay practices that combine base salary, annual performance-based cash bonuses tied to corporate goals, and equity incentives including stock options and RSUs with service and market-based vesting conditions. The company cites 2025 clinical and financing milestones and a 95% corporate performance score used to determine bonuses; management views its pay design as aligned with long-term stockholder value and retention. The board recommends a 'FOR' vote, arguing that compensation practices are market-competitive, include clawback and anti-hedging policies, and use independent compensation consultants and peer benchmarking to mitigate excessive risk-taking. Because the vote is advisory, it does not bind the board, but the compensation committee will consider stockholder feedback for future decisions. The proposal reflects typical 'say-on-pay' considerations in corporate governance and arises in the context of significant clinical progress, equity grants with market-based vesting tied to stock performance, and substantial capital raises during 2025.

3. 3

   Approval of Amendment to Increase Authorized Common Shares from 200,000,000 to 400,000,000

   ManagementBoard: FOR

   Amend Restated Certificate of Incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares.

   More detail

   Management requests shareholder approval to amend the charter to double authorized common shares to 400 million (and total authorized to 410 million including preferred), citing operational flexibility to support financings, equity incentive plans, potential strategic transactions and other corporate needs without the delay and cost of seeking shareholder approval in the future. The board emphasizes that substantial issuance is anticipated for equity compensation, the at-the-market offering, and potential future capital raises given the company’s cash runway goals and $1.1 billion in cash as of year-end. Management notes there are currently only ~5.9 million unreserved shares available, which could constrain future financing options. While dilution concerns exist, the board argues the amendment is prudent to preserve financial agility, and contends that the increase could deter hostile takeovers but is primarily for legitimate operational flexibility. The board recommends a 'FOR' vote and frames the amendment as necessary to support growth, capital strategy, and employee compensation while cautioning that future issuances could dilute existing shareholders and affect share price.

4. 4

   Approval of Amendment to Provide for Officer Exculpation

   ManagementBoard: FOR

   Amend Restated Certificate of Incorporation to expand exculpation provision to include certain officers to the fullest extent permitted by Delaware law, excluding bad faith and other specified exceptions.

   More detail

   This management proposal seeks shareholder approval to amend the charter to extend limited monetary liability protection—already afforded to directors—to certain officers to the fullest extent permitted by the DGCL. Management’s stated rationale is recruitment and retention of senior executives in a competitive market and to harmonize officers’ protections with those of directors, thereby mitigating litigation risks from hindsight-based claims and discouraging plaintiffs’ counsel from adding officers to suits after director claims are dismissed. The amendment expressly excludes exculpation for claims brought by the company, derivative claims, breaches of loyalty, acts not in good faith, intentional misconduct, knowing violations of law, and transactions where improper personal benefit is alleged, limiting its protective scope. The board argues that the change is narrowly tailored, consistent with many peers, and would not impair stockholder remedies for derivative actions or other serious misconduct, while potentially reducing frivolous litigation and improving officer recruitment. Shareholders should weigh the recruitment/retention benefits and reduced litigation costs versus concerns that expanded exculpation could reduce officer accountability or shift litigation consequences. The board recommends a 'FOR' vote.

5. 5

   Ratification of Appointment of Independent Registered Public Accountants

   ManagementBoard: FOR

   Ratify the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for fiscal 2026.

Upcoming shareholder meetings at Dyne Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Dyne Therapeutics Inc 2026 annual meeting?

Dyne Therapeutics Inc (DYN) holds its 2026 annual shareholder meeting on Friday, June 5, 2026.

What is the record date for the Dyne Therapeutics Inc 2026 meeting?

The record date for the Dyne Therapeutics Inc 2026 meeting is Tuesday, April 7, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Dyne Therapeutics Inc's 2026 meeting?

The board is presenting 3 director nominees at the Dyne Therapeutics Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Dyne Therapeutics Inc 2026 meeting?

Shareholders will vote on 5 proposals at the Dyne Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.